HOFFMANN MATTHIAS,FIEGEN DENNIS,KLICIC JASNA,SCHAENZLE GERHARD,EAST STEPHEN PETER,SCOTT ROBERT JOHN,DAHMANN GEORG,HANDSCHUH SANDRA RUTH,LINZ GUENTER,SCHNAPP ANDREAS,MAZANETZ MICHAEL PHILIP,WALKER EDWA
申请号：
ZA201204793
公开号：
ZA201204793B
申请日:
2012.06.27
申请国别(地区):
ZA
年份:
2013
代理人:
摘要：
The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among &mdash；O&mdash；R3 or &mdash；NR3R4, R3 is C1-6-alkyl which is substituted by R5 and R6, R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, &mdash；C1-6-alkylen-O&mdash；C1-3-alkyl, C1-3-haloalkyl, R6 is ring X wherein n is either 0 or 1, and is a either a single or a double bond and wherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, &mdash；C1-3-alkyl, &mdash；C1-3-haloalkyl, &mdash；O&mdash；C1-3-alkyl, &mdash；C1-3-alkanol and halogen, and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well as pharmaceutical compositions containing these compounds.
